Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of August 2022
Date Filed: August 31, 2022
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document serves primarily as a procedural submission rather than a financial results report.
Material Changes
No material financial changes or operational updates are detailed in the provided text. The filing incorporates by reference specific Registration Statements (Form S-8 and Form F-3) but does not list comparative period data.
Guidance, Outlook, and Risks
Management Commentary: None provided in this specific filing text.
Exhibits Submitted: Exhibit 99.1 includes "Appendix 4G and Corporate Governance Statement 2022".
Risks and Contingencies: No specific risks or contingencies are enumerated in the provided text.
Investor Verification Checklist
- Verify the contents of the referenced Registration Statements (Form S-8: 333-251073, 333-248980, 333-228671; Form F-3: 333-251647, 333-249311, 333-231417, 333-250076) for detailed financial data.
- Review the attached "Corporate Governance Statement 2022" (Exhibit 99.1) for governance updates.
- Confirm the company's status as a development stage enterprise and its current cash runway via recent Form 20-F filings.